{"id":"placebo-for-ramucirumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the efficacy and safety profile of the active drug (in this case, Ramucirumab) by comparison against a non-therapeutic baseline. Any observed effects are attributed to natural disease progression, regression to the mean, or the placebo effect rather than direct drug action.","oneSentence":"Placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:30.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02711553","phase":"PHASE2","title":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-05-19","conditions":"Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer","enrollment":309},{"nctId":"NCT03560973","phase":"PHASE2","title":"A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2016-12-22","conditions":"Mesothelioma","enrollment":164},{"nctId":"NCT00703326","phase":"PHASE3","title":"Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08-06","conditions":"Breast Cancer","enrollment":1144},{"nctId":"NCT02314117","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01-20","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":645},{"nctId":"NCT00917384","phase":"PHASE3","title":"Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Gastric Cancer, Adenocarcinoma","enrollment":355},{"nctId":"NCT01168973","phase":"PHASE3","title":"A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Non-Small Cell Lung Cancer","enrollment":1253},{"nctId":"NCT01140347","phase":"PHASE3","title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Hepatocellular Carcinoma","enrollment":565},{"nctId":"NCT01246960","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Stomach Cancer, Esophageal Cancer","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":164,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}